CA2598016A1 - Amorphous lercanidipine hydrochloride - Google Patents

Amorphous lercanidipine hydrochloride Download PDF

Info

Publication number
CA2598016A1
CA2598016A1 CA002598016A CA2598016A CA2598016A1 CA 2598016 A1 CA2598016 A1 CA 2598016A1 CA 002598016 A CA002598016 A CA 002598016A CA 2598016 A CA2598016 A CA 2598016A CA 2598016 A1 CA2598016 A1 CA 2598016A1
Authority
CA
Canada
Prior art keywords
lercanidipine hydrochloride
lercanidipine
amorphous
amorphous lercanidipine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002598016A
Other languages
English (en)
French (fr)
Inventor
Amedeo Leonardi
Gianni Motta
Fabio Berlati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati Ireland Ltd
Original Assignee
Recordati Ireland Limited
Amedeo Leonardi
Gianni Motta
Fabio Berlati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36585434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2598016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Ireland Limited, Amedeo Leonardi, Gianni Motta, Fabio Berlati filed Critical Recordati Ireland Limited
Publication of CA2598016A1 publication Critical patent/CA2598016A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/04—Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
CA002598016A 2005-02-25 2006-02-24 Amorphous lercanidipine hydrochloride Abandoned CA2598016A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65683605P 2005-02-25 2005-02-25
US60/656,836 2005-02-25
PCT/EP2006/001782 WO2006089787A1 (en) 2005-02-25 2006-02-24 Amorphous lercanidipine hydrochloride

Publications (1)

Publication Number Publication Date
CA2598016A1 true CA2598016A1 (en) 2006-08-31

Family

ID=36585434

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002598016A Abandoned CA2598016A1 (en) 2005-02-25 2006-02-24 Amorphous lercanidipine hydrochloride

Country Status (32)

Country Link
US (1) US7820701B2 (el)
EP (1) EP1856051B1 (el)
JP (1) JP2008531515A (el)
KR (1) KR20070105979A (el)
CN (1) CN101124204A (el)
AR (1) AR052918A1 (el)
AU (1) AU2006218026B9 (el)
BR (1) BRPI0608138A2 (el)
CA (1) CA2598016A1 (el)
CY (1) CY1122429T1 (el)
DK (1) DK1856051T3 (el)
EA (1) EA014383B1 (el)
ES (1) ES2339213T3 (el)
HR (1) HRP20192302T1 (el)
HU (1) HUE046910T2 (el)
IL (1) IL184349A0 (el)
LT (1) LT1856051T (el)
ME (1) ME03659B (el)
MX (1) MX2007010093A (el)
MY (1) MY142129A (el)
NO (1) NO344559B1 (el)
NZ (1) NZ556667A (el)
PE (1) PE20061014A1 (el)
PL (1) PL1856051T3 (el)
PT (1) PT1856051T (el)
RS (1) RS59654B1 (el)
SI (1) SI1856051T1 (el)
TW (1) TW200640861A (el)
UA (1) UA90130C2 (el)
UY (1) UY29401A1 (el)
WO (1) WO2006089787A1 (el)
ZA (1) ZA200708127B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532248B1 (en) 2002-07-26 2009-04-01 Novartis Vaccines and Diagnostics, Inc. Modified small interfering rna molecules and methods of use
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
KR20080048065A (ko) 2005-09-16 2008-05-30 그렌마크 파머수티칼스 엘티디. 다형 형태의 염산 레르카니디핀 및 이것의 제조방법
DK2046745T3 (da) * 2006-08-04 2014-01-20 Recordati Ireland Ltd Fremgangsmåde til fremstilling af amorft lercanidipin-hydrochlorid
EP2101771A2 (en) * 2006-12-06 2009-09-23 Torrent Pharmaceuticals Ltd Stable lercanidipine formulation
EP2121575A2 (en) * 2007-03-05 2009-11-25 Actavis Group PTC EHF Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate
ES2531040T3 (es) * 2009-05-12 2015-03-10 Corcept Therapeutics Inc Formas sólidas y procedimiento de preparación
DE102010005124A1 (de) * 2010-01-19 2012-03-01 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung umfassend Lercanidipin
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
EP3039011A1 (en) * 2013-08-29 2016-07-06 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
IT1274480B (it) 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US5912351A (en) 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
ITMI20011727A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
US20030069285A1 (en) * 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US20030180355A1 (en) * 2001-10-16 2003-09-25 Amedeo Leonardi Combination therapy for hypertension
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
TW200616681A (en) 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
KR100651212B1 (ko) 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
KR20080048065A (ko) 2005-09-16 2008-05-30 그렌마크 파머수티칼스 엘티디. 다형 형태의 염산 레르카니디핀 및 이것의 제조방법
EP1963254A2 (en) 2005-09-21 2008-09-03 Torrent Pharmaceuticals Ltd Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
DK2046745T3 (da) 2006-08-04 2014-01-20 Recordati Ireland Ltd Fremgangsmåde til fremstilling af amorft lercanidipin-hydrochlorid

Also Published As

Publication number Publication date
AU2006218026B2 (en) 2009-04-02
PE20061014A1 (es) 2006-10-03
KR20070105979A (ko) 2007-10-31
AU2006218026B9 (en) 2011-10-27
PL1856051T3 (pl) 2020-05-18
US7820701B2 (en) 2010-10-26
NZ556667A (en) 2009-10-30
PT1856051T (pt) 2020-01-07
EP1856051A1 (en) 2007-11-21
RS59654B1 (sr) 2020-01-31
BRPI0608138A2 (pt) 2009-11-17
CN101124204A (zh) 2008-02-13
WO2006089787A1 (en) 2006-08-31
TW200640861A (en) 2006-12-01
LT1856051T (lt) 2020-01-10
IL184349A0 (en) 2007-10-31
ES2339213T3 (es) 2020-05-28
AU2006218026A1 (en) 2006-08-31
HRP20192302T1 (hr) 2020-03-06
EA200701687A1 (ru) 2008-02-28
ME03659B (me) 2021-01-20
JP2008531515A (ja) 2008-08-14
CY1122429T1 (el) 2021-01-27
EA014383B1 (ru) 2010-10-29
EP1856051B1 (en) 2019-11-13
NO344559B1 (no) 2020-02-03
NO20074874L (no) 2007-11-26
US20060211742A1 (en) 2006-09-21
UA90130C2 (ru) 2010-04-12
UY29401A1 (es) 2006-06-30
ZA200708127B (en) 2008-11-26
DK1856051T3 (da) 2020-01-02
MY142129A (en) 2010-09-30
HUE046910T2 (hu) 2020-04-28
MX2007010093A (es) 2007-10-12
AR052918A1 (es) 2007-04-11
SI1856051T1 (sl) 2020-02-28
ES2339213T1 (es) 2010-05-18

Similar Documents

Publication Publication Date Title
AU2006218026B9 (en) Amorphous lercanidipine hydrochloride
RU2241701C1 (ru) Камзилат амлодипина, способ его получения и фармацевтическая композиция на его основе
JPH037668B2 (el)
US7579475B2 (en) S-(-)-amlodipine nicotinate and process for the preparation thereof
US6852737B2 (en) Crude and crystalline forms of lercanidipine hydrochloride
AU2002327924C1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
AU2002243069A1 (en) Novel amlodipine camsylate and method for preparing thereof
EP0521310B1 (en) Solid dispersion tablets containing 1,4-dihydropyridine derivatives and process for the preparation thereof
US20060199849A1 (en) Solid lercanidipine free base
EP1587792B1 (en) Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof
US6538012B2 (en) Amlodipine hemimaleate
RU2403241C1 (ru) (s)-(-)-амлодипина камзилат или его гидрат и фармацевтическая композиция, включающая их
KR100467669B1 (ko) 암로디핀의 유기산염
US20040058967A1 (en) Crystalline organic acid salt of amlodipine
US20030022922A1 (en) Amlodipine free base
AU2001100436A4 (en) Amlodipine hemimaleate

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140123